Intracoronary delivery of eptifibatide with the ClearWayA RX infusion catheter

Catheterization and Cardiovascular Interventions

Volumn 77, Issue 2, 2011, Pages 222-227

  Deibele, Albert J ^a   Michael Gibson, C ^b  

^a Duluth Clinic   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

acute coronary syndromes; GP IIb IIIa inhibitors; local drug delivery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; EPTIFIBATIDE; HEPARIN; HIRULOG; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; BALLOON CATHETER; BARE METAL STENT; BLOOD CLOT LYSIS; BOLUS INJECTION; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY OBSTRUCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RETENTION; DYSPNEA; HUMAN; INFUSION BALLOON CATHETER; INTRACORONARY INFUSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; RECEPTOR OCCUPANCY; STENT THROMBOSIS; THORAX PAIN;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; CATHETERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; INFUSIONS, PARENTERAL; MALE; METALS; MICROCIRCULATION; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; STENTS; TREATMENT OUTCOME;

EID: 79751494142     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22760     Document Type: Article

References (13)

1. Okamura A, Ito H, Iwakura K, Kawano S, Inoue K, Maekawa Y, Ogihara T, Fujii K,. Detection of embolic particles with the doppler guide wire during coronary intervention in patients with acute myocardial infarction: Efficacy of distal protection device. J Am Coll Cardiol 2005; 45: 212-215. (Pubitemid 40094727)
2. Okamura A, Ito H, Iwakura K, Kurotobi T, Koyama Y, Date M, Higuchi Y, Inoue K, Fujii K,. Clinical implications of distal embolization during coronary interventional procedures in patients with acute myocardial infarction. Quantitative study with doppler guidewire. J Am Coll Cardiol Intv 2008; 1: 268-272.
3. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo controlled trial. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 2000; 356: 2037-2044.
4. Moser M, Bertram U, Peter K, Bode C, Ruef J,. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 2003; 41: 586-592. (Pubitemid 36373796)
5. Goto S, Tamura N, Ishida H,. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 44: 316-323. (Pubitemid 38950589)
6. Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK,. Variability of platelet aggregate dispersal with GP IIb/IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 2009; 7: 983-991.
7. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM,. Intracoronary eptifibatide bolus administration for acute coronary syndromes with evaluation of platelet GP IIb/IIIa receptor occupancy and platelet function. The Intracornary Eptifibatide (ICE) Trial. Circulation 2010; 121: 784-791.
8. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G,. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. The randomized leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118: 49-57.
9. Prati F, Ramazzatti V, Gil R, Pawlowsky T, La Manna A, Capodanno D,. Tamburino COCKTAIL study: Optimal treatment of intracoronary thrombosis with local abciximab infusion through the ClearWay system. San Francisco: Transcatheter Cardiovascular Therapeutics-TCT Conference; Sept 21-25, 2009.
10. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II (IMPACT II) Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-1428.
11. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators. Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
12. Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade (EPILOG) Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
13. Gibson CM, Jennings LK, Murphy SA, Lorentz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E,. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction. An INTEGRITI (integrilin and tenecteplase in acute myocardial infarction) Substudy. Circulation 2004; 110: 679-684. (Pubitemid 39056266)